Berghmans R, Berg M, van den Burg M, ter Meulen R
Institute for Bioethics, Health Ethics and Philosophy, Department of Caring Sciences, University of Maastricht, Maastricht, the Netherlands.
J Med Ethics. 2004 Apr;30(2):146-50. doi: 10.1136/jme.2003.007047.
This article discusses ethical issues which are raised as a result of the introduction of economic evidence in mental health care in order to rationalise clinical practice. Cost effectiveness studies and guidelines based on such studies are often seen as impartial, neutral instruments which try to reduce the influence of non-scientific factors. However, such rationalising instruments often hide normative assumptions about the goals of treatment, the selection of treatments, the role of the patient, and the just distribution of scarce resources. These issues are dealt with in the context of increased control over clinical practice by third parties. In particular, health insurers have a great interest in economic evidence in clinical care settings in order to control access to and quality of (mental) health care. The authors conclude that guideline setting and cost effectiveness analysis may be seen as important instruments for making choices in health care, including mental health care, but that such an approach should always go hand in hand with a social and political debate about the goals of medicine and (mental) health care. This article is partly based on the results of a research project on the normative aspects of guideline setting in psychiatry and cardiology which was conducted under the guidance of the Royal Dutch Medical Association.
本文讨论了在精神卫生保健中引入经济证据以合理化临床实践所引发的伦理问题。成本效益研究以及基于此类研究的指南通常被视为公正、中立的工具,旨在减少非科学因素的影响。然而,此类合理化工具往往隐藏着关于治疗目标、治疗选择、患者角色以及稀缺资源公正分配的规范性假设。这些问题是在第三方对临床实践控制增强的背景下进行探讨的。特别是,健康保险公司对临床护理环境中的经济证据有着浓厚兴趣,以便控制(精神)卫生保健的获取和质量。作者得出结论,制定指南和成本效益分析可被视为在包括精神卫生保健在内的卫生保健中做出选择的重要工具,但这种方法应始终与关于医学和(精神)卫生保健目标的社会和政治辩论相结合。本文部分基于在荷兰皇家医学协会指导下进行的一项关于精神病学和心脏病学指南制定规范性方面的研究项目结果撰写而成。